XARELTO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XARELTO (XARELTO).
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
| Metabolism | Metabolized via CYP3A4, CYP2J2, and CYP-independent mechanisms; also undergoes hydrolysis by amidases. |
| Excretion | Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h. |
| Half-life | Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment). |
| Protein binding | Bound to albumin and alpha-1-acid glycoprotein; total protein binding approximately 92–95% (mean 93%). |
| Volume of Distribution | Volume of distribution: Approximately 50 L (0.7 L/kg). Consistent with moderate distribution into extravascular tissues, primarily in liver, kidneys, and gastrointestinal tract. |
| Bioavailability | Oral bioavailability: 80–100% (mean 80% under fasting conditions, 100% with food). Bioavailability unaffected by food; take with food reduces variability. |
| Onset of Action | Oral: Peak plasma concentration (Cmax) achieved 2–4 hours post-dose. Anticoagulant effect (anti-Factor Xa activity) measurable within 2 hours. |
| Duration of Action | Anticoagulant effect lasts approximately 12–24 hours post-dose. Clinical note: Twice-daily regimen maintains therapeutic levels; missed dose effect may persist for next scheduled dose. |
| Action Class | Oral Factor Xa Inhibitors |
| Brand Substitutes | Ifaxa 10mg Tablet, Rivatroy 10 Tablet, Rivaban 10 Tablet, Rivastar 10mg Tablet, Rivaford 10mg Tablet, Rivaban 20 Tablet, Rivolas 20 Tablet, Ricosprin 20 Tablet, Rixar 20 Tablet, Cameriv 20mg Tablet, Rivatroy 15 Tablet, Rivatop 15mg Tablet, Rivaban 15 Tablet, Cameriv 15mg Tablet, Flovas 15mg Tablet, Rivolas 15 Tablet |
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
| Dosage form | FOR SUSPENSION |
| Renal impairment | CrCl 15-50 mL/min: 15 mg once daily for atrial fibrillation; CrCl <15 mL/min: avoid use; for treatment of DVT/PE: no adjustment unless CrCl <30 mL/min, then avoid. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: avoid use; Child-Pugh C: contraindicated. |
| Pediatric use | Weight-based (for VTE treatment): <50 kg: 15 mg once daily; ≥50 kg: 20 mg once daily; for thromboprophylaxis: 10 mg once daily (weight ≥50 kg); dosing not established for age <18 years for all indications. |
| Geriatric use | No specific dose adjustment based on age alone; monitor renal function closely; increased risk of bleeding in elderly; use 15 mg once daily for atrial fibrillation if CrCl 15-50 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XARELTO (XARELTO).
| Breastfeeding | Excreted in human milk at low levels; estimated relative infant dose (RID) 0.5-1%. Milk-to-plasma ratio (M/P) not established. Due to potential for bleeding in infant, breastfeeding is not recommended. Use alternative anticoagulation if necessary. |
| Teratogenic Risk | Pregnancy category X. Rivaroxaban is contraindicated in pregnancy. First trimester: Risk of hemorrhage and potential teratogenic effects based on animal studies. Second and third trimesters: Increased risk of maternal hemorrhage, placental abruption, and fetal hemorrhage. Warfarin embryopathy is not associated; however, direct oral anticoagulants cross the placenta and may cause adverse fetal outcomes. |
■ FDA Black Box Warning
Premature discontinuation of XARELTO increases the risk of thrombotic events. Epidural or spinal hematomas may occur in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture.
| Serious Effects |
Active pathological bleeding; hypersensitivity to rivaroxaban; severe hypersensitivity reaction (e.g., anaphylactic reactions); patients with mechanical prosthetic heart valves; moderate to severe hepatic impairment (Child-Pugh B and C) or hepatic disease associated with coagulopathy.
| Precautions | Risk of bleeding including fatal bleeding; risk of epidural/spinal hematoma with neuraxial procedures; increased risk of thrombotic events with premature discontinuation; prosthetic heart valves not studied; pregnancy and lactation considerations; renal impairment dose adjustment required; hepatic impairment should be used with caution. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of bleeding (maternal and fetal), fetal growth restriction via ultrasound, and anticoagulant activity (anti-Xa assay if available). Close monitoring of maternal hemoglobin and coagulation parameters not required as routine; clinical vigilance for hemorrhage is paramount. |
| Fertility Effects | No specific data in humans. In animal studies, no effect on fertility was observed. Theoretical potential for impaired fertility due to anticoagulation effects on ovulation or implantation is unlikely. |